Back to Agenda
Session 4. ASEAN Townhall : What is the Influence of Emerging Regulatory Strategies and Trends on the Surveillance of Medicines after They Have Been Approved?
Session Chair(s)
Thean Soo Lo
Regulatory Affairs Management Consultant, TS Consulting, Singapore
Helene Sou, MSC, RAC
Global Regulatory Policy and Innovation, Takeda Pharmaceutical Company Limited., Singapore
Speaker(s)
Muzzaffar Halli
Senior Manager RA and PV, Novo Nordisk, Malaysia
A Comprehensive Approach to the Benefit-Risk Assessment of New Drugs throughout Its Lifecycle
Asmaa Asim, MBA
Director Regulatory Affairs and Pharmacovigilance, Organon Asia Pacific Pte Ltd, Singapore
Sreemanee Raaj Dorajoo, PHD
Senior Data Analyst, Vigilance and Compliance Branch, Health Sciences Authority (HSA), Singapore
A New Era of Pharmacovigilance – Learnings and Opportunities (Singapore’s Perspective)
Marakot Papassiripan
Pharmacist, Professional level Biological product sub-div Bureau of Drug Control, Thai FDA, Thailand
MA. THERESA. PIA C. YAP
Food-Drug Regulations Officer II – IV, LRD, CDRR, FDA Philippines, Philippines
Tri Asti Isnariani, MPHARM
Director of Drug, Narcotics, Psychotropics, Addictive Substances Standardization, Badan Pengawas Obat dan Makanan (BPOM), Indonesia
Have an account?